Citation Tools
PDFPoster Presentations
Rheumatoid arthritis - non biologic treatment and small molecules
SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure